Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
05 nov. 2024 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
04 juin 2024 13h00 HE
|
HOOKIPA Pharma Inc.
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with...
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
23 mai 2024 17h01 HE
|
HOOKIPA Pharma Inc.
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile...
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
25 avr. 2024 07h01 HE
|
HOOKIPA Pharma Inc.
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback ...
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
11 avr. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
PV-10 demonstrated significant anti-tumor activity in vivo in head and neck cancers KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
10 avr. 2024 07h01 HE
|
HOOKIPA Pharma Inc.
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK...
Global Oncologists Market Report 2024: Precision Medicine and Therapeutic Advancements Drive Expansion to $22.72 Billion by 2028
13 mars 2024 12h11 HE
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global oncologists market has grown steadily in...
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
07 mars 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in vivo KNOXVILLE, TN, March 07,...
$2+ Bn PD-1 Resistant Head and Neck Cancer Markets - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2022 and 2023-2028F
12 févr. 2024 04h14 HE
|
Research and Markets
Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...
Oncologists Global Market to Reach $27.51 Billion by 2032; Asia-Pacific and North America Lead Growth
29 janv. 2024 11h35 HE
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering. The global oncologists...